 |
|
|
| |
Health Technology Assessment of New Long-Acting, Directly-Observed HIV Treatments in Canada:
Impact of Real-World Adherence to Daily Oral Therapy on Treatment, Transmission and Cost-Effectiveness
|
| |
| |
IDWeek 2020 Oct 21-25 virtual
Reported by Jules Levin
Erin Arthurs1, Ben Parker2, Ian Jacob2, Olivia Hayward2, Debbie Becker3, Amy Lee3, Joann Ban1, Sarah-Jane Anderson4, Vasiliki Chounta5, Nicolas Van de Velde5
1.GlaxoSmithKline, Mississauga, ON, Canada; 2.HEOR Ltd., Cardiff, Wales, UK; 3.Quadrant Health Economics Inc., Cambridge, ON, Canada; 4. GlaxoSmithKline, Brentford, UK; 5. ViiV Healthcare, Brentford, UK
|
| |
|
|
|
|
|
